Braveheart Investment Group PLC (AIM:BRH) provided an update on PhaseFocus Holdings Limited, a company in which it owns a 42.6% stake, as it plans to expand production facilities in early 2022 to meet anticipated demand.
PhaseFocus, which has developed a series of imaging techniques with a range of applications including live cell imaging, engineering metrology and electron microscopy, has signed a distribution agreement with Swedish bio-convergence company BICO Group.
Braveheart said this deal has given the Nottingham-based business an “excellent platform for driving sales growth across the EU and USA”.
Braveheart said that BICO’s CYTENA arm is promoting Livecyte, PhaseFocus’ label free content system very strongly, with three Livecyte cell imaging systems to be shipped to CYTENA to be distributed to centres in the EU and US.
Demonstrations to public health laboratories by CYTENA are ongoing, with the potential sales pipeline for 2022 said to be growing.
PhaseFocus' UK distributor, Lablogic, is meanwhile targeting sales of Livecyte systems to other UK university-based researchers, following the recent sale of one of the systems to St George's, University of London.
Additionally, distributors in China, Japan, Australia and Italy are also experiencing good levels of enquiry, according to Braveheart.